An editorial reading of a research peptide

What this publication is

TB-500 Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin Beta-4 and the synthetic seven-amino-acid fragment marketed as TB-500. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The modifier prescribed in the domain name is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. The site does not write prescriptions, does not connect readers to prescribers, and does not facilitate compounding or telehealth. It writes about the regulatory and research record that surrounds the prescription question. As of this publication, the answer to that question in the United States is that no prescription is available, because no FDA-approved TB-500 product exists and the substance is not eligible for pharmacy compounding ^[26].

Editorial standards

The site is built around three editorial commitments.

Sources are primary. Every quantitative claim — every dose, every percentage, every endpoint result, every regulatory date — is traced to a peer-reviewed paper, a registered clinical trial record, or a published FDA guidance document. The /references page lists twenty-seven such sources with DOIs and registry identifiers.

Distinctions are preserved. The fragment-versus-parent-peptide distinction is treated as a structural fact about the field, not a footnote. The Phase I safety record for full-length Tβ4 ^[13][14] is not extrapolated to the seven-residue fragment. The animal data for the parent peptide is not represented as fragment data. Where vendor literature collapses the distinction, the site names the collapse.

The regulatory record is current. The September 29, 2023 FDA Category 2 placement of Thymosin Beta-4, Fragment (LKKTETQ) on the Interim 503A Bulks List ^[26] is the operative United States fact for the prescription and compounding questions, and the site treats it as such. The 2024 PCAC review of related peptides is also tracked ^[27]. If the FDA position changes, the site will update.

What this publication isn't

It is not a clinic. There are no clinicians on staff. There is no clinical team. There are no physicians, pharmacists, or other licensed healthcare professionals associated with this publication who provide care to readers.

It is not a pharmacy. The site does not manufacture, distribute, sell, compound, repackage, or ship any product. It does not collect orders. It does not maintain a formulary. It does not partner with compounding pharmacies or outsourcing facilities.

It is not a vendor. The site has no commercial relationship with any peptide manufacturer, research-chemical supplier, telehealth platform, or licensed pharmaceutical company. It does not run affiliate links to product pages.

It is not medical advice. Nothing on this site constitutes medical advice, prescribing recommendations, clinical guidance, or a substitute for evaluation by a qualified healthcare professional. Readers seeking care should consult a licensed clinician.

How the wall labels read

Each page is structured as a wall-label reading of one part of the record. The hero on each page carries an eyebrow section number and a one-line wall label. The body proceeds in inverted-pyramid order: the most important fact first, the supporting evidence underneath, the unresolved questions named at the end. Inline citation markers in square brackets point to the references index, which is reachable from the navigation on every page.

The quiet visual register — black-on-cream typography, a single burgundy hairline accent, generous whitespace as the framing device — is the editorial argument enacted in design. TB-500 is a research peptide whose prescription status is fundamentally a category absence. The site exhibits the absence rather than performing it.